MedinCell S.A. (EPA:MEDCL)
France
· Delayed Price · Currency is EUR | Market Cap | 557.10M |
| Revenue (ttm) | 27.73M |
| Net Income (ttm) | -18.44M |
| Shares Out | 33.06M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | 82.43 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 49,243 |
| Average Volume | 86,506 |
| Open | 16.83 |
| Previous Close | 16.85 |
| Day's Range | 16.46 - 16.97 |
| 52-Week Range | 12.00 - 19.00 |
| Beta | 1.08 |
| RSI | 56.01 |
| Earnings Date | Jun 17, 2025 |
About MedinCell
MedinCell S.A., a pharmaceutical company, develops long acting injectables in various therapeutic areas in France. It develops solutions based on BEPO, a long-acting injectable technology; and offers UZEDY (mdc-IRM) for the treatment of schizophrenia in adults. The company’s products in development include mdc-CWM, a sustained-release formulation of celecoxib in Phase III trials for use in the treatment of reduction of postoperative pain and inflammation; and mdc-TJK, a subcutaneous injection that is in Phase III clinical trials for use in the ... [Read more]
Financial Performance
In 2024, MedinCell's revenue was 27.73 million, an increase of 132.12% compared to the previous year's 11.95 million. Losses were -18.44 million, -26.36% less than in 2023.
Financial StatementsNews
Teva Pharmaceuticals reports completion of phase 3 trial for Olanzapine LAI in Schizophrenia
Update on the completion of pivotal phase 3 trial for olanzapine Long-Acting Injectable in schizophrenia by Medincell's partner Teva Pharmaceuticals.